JP2009536193A - 予防若しくは治療の形態で投与されるα−ＭＳＨを用いた、改善の余地のある多様な病理学的過程に関する治療におけるニコチン、そのアナログ、その前駆体またはその誘導体の使用 - Google Patents

予防若しくは治療の形態で投与されるα−ＭＳＨを用いた、改善の余地のある多様な病理学的過程に関する治療におけるニコチン、そのアナログ、その前駆体またはその誘導体の使用 Download PDF

Info

Publication number
JP2009536193A
JP2009536193A JP2009509455A JP2009509455A JP2009536193A JP 2009536193 A JP2009536193 A JP 2009536193A JP 2009509455 A JP2009509455 A JP 2009509455A JP 2009509455 A JP2009509455 A JP 2009509455A JP 2009536193 A JP2009536193 A JP 2009536193A
Authority
JP
Japan
Prior art keywords
msh
nicotine
derivatives
precursors
analogs
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009509455A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009536193A5 (enExample
Inventor
ヘレラ，アルツロ ソリス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38667940&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2009536193(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Individual filed Critical Individual
Publication of JP2009536193A publication Critical patent/JP2009536193A/ja
Publication of JP2009536193A5 publication Critical patent/JP2009536193A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/465—Nicotine; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Molecular Biology (AREA)
  • Transplantation (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
JP2009509455A 2006-05-08 2006-05-08 予防若しくは治療の形態で投与されるα−ＭＳＨを用いた、改善の余地のある多様な病理学的過程に関する治療におけるニコチン、そのアナログ、その前駆体またはその誘導体の使用 Pending JP2009536193A (ja)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/MX2006/000031 WO2007129879A1 (es) 2006-05-08 2006-05-08 EL USO DE LA NICOTINA, SUS ANÁLOGOS, SUS PRECURSORES O SUS DERIVADOS EN EL TRATAMIENTO DE DIVERSOS PROCESOS PATOLÓGICOS SUSCEPTIBLES DE MEJORAR CON α-MSH ADMINISTRADA EN FORMA PROFILÁCTICA O TERAPÉUTICA.

Publications (2)

Publication Number Publication Date
JP2009536193A true JP2009536193A (ja) 2009-10-08
JP2009536193A5 JP2009536193A5 (enExample) 2011-03-24

Family

ID=38667940

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009509455A Pending JP2009536193A (ja) 2006-05-08 2006-05-08 予防若しくは治療の形態で投与されるα−ＭＳＨを用いた、改善の余地のある多様な病理学的過程に関する治療におけるニコチン、そのアナログ、その前駆体またはその誘導体の使用

Country Status (13)

Country Link
US (4) US20090197921A1 (enExample)
EP (4) EP2801360B1 (enExample)
JP (1) JP2009536193A (enExample)
KR (1) KR20130116374A (enExample)
CN (1) CN101437515B (enExample)
AU (1) AU2006343439B2 (enExample)
BR (1) BRPI0621650A2 (enExample)
CA (1) CA2651580C (enExample)
DK (1) DK2801360T3 (enExample)
ES (1) ES2683323T3 (enExample)
MX (1) MX2008011473A (enExample)
NZ (1) NZ572366A (enExample)
WO (1) WO2007129879A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8557804B2 (en) 2002-03-25 2013-10-15 Universite Laval Nicotinic receptor agonists for the treatment of inflammatory diseases
US8039459B2 (en) 2004-07-15 2011-10-18 Universite Laval Nicotinic receptor agonists for the treatment of inflammatory diseases
US20110206642A1 (en) * 2009-10-15 2011-08-25 Cohava Gelber Preventing obesity-related metabolic syndrome with melagonesis
US9668969B1 (en) 2012-02-22 2017-06-06 Arturo Solis Herrera Methods of using QIAPINE
WO2016038441A1 (en) 2014-09-09 2016-03-17 Arturo Solis Herrera Methods for treating and preventing ocular diseases, disorders, and conditions with melanin and melanin analogs, precursors, and derivatives
HK1258883A1 (zh) 2016-04-12 2019-11-22 A‧索利斯‧赫雷拉 用烟硷乙酰胆硷受体激动剂治疗鼻和鼻旁粘膜病症的组合物和方法
LU101520B1 (en) * 2019-12-02 2021-06-07 Herrera Arturo Solis (S)-3-[1-Methylpyrrolidin-2-yl]pyridine, analogues thereof, precursors thereof, or its derivatives, for the use as a pharmaceutical in form of a homogeneous, viscous, semi-solid topical medication and topical medication

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004510695A (ja) * 2000-05-23 2004-04-08 ノース・ショア−ロング・アイランド・ジューイッシュ・リサーチ・インスティテュート コリン作動薬および迷走神経刺激による炎症性サイトカイン産生の阻害
JP2004523588A (ja) * 2001-03-23 2004-08-05 ユニヴェルシテ ラヴァル 炎症性疾患治療用のニコチン性受容体アゴニスト

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030185761A1 (en) * 1997-10-01 2003-10-02 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating pain
SE0104388D0 (sv) * 2001-12-27 2001-12-27 Pharmacia Ab New formulation and use and manufacture thereof
AU2005225458B2 (en) * 2004-03-25 2008-12-04 The Feinstein Institutes For Medical Research Neural tourniquet

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004510695A (ja) * 2000-05-23 2004-04-08 ノース・ショア−ロング・アイランド・ジューイッシュ・リサーチ・インスティテュート コリン作動薬および迷走神経刺激による炎症性サイトカイン産生の阻害
JP2004523588A (ja) * 2001-03-23 2004-08-05 ユニヴェルシテ ラヴァル 炎症性疾患治療用のニコチン性受容体アゴニスト

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
JPN6012016677; ＬＡＭＡＣＺ，　Ｍ．　ｅｔ　ａｌ．: Ａｎｎａｌｓ　ｏｆ　ｔｈｅ　Ｎｅｗ　Ｙｏｒｋ　Ａｃａｄｅｍｙ　ｏｆ　Ｓｃｉｅｎｃｅｓ Ｖｏｌ．６８０, 1993, ｐｐ．５２０-５２３ *
JPN6012016681; Ｍａｒｔｙ，　Ｍ．Ａ．　ｅｔ　ａｌ．: Ｐｈａｒｍａｃｏｌｏｇｙ　Ｂｉｏｃｈｅｍｉｓｔｒｙ　＆　Ｂｅｈａｖｉｏｒ Ｖｏｌ．２２, 1985, ｐｐ．３１７-３２５ *
JPN6012016684; Ｇａｒｎｉｅｒ，　Ｍ．　ｅｔ　ａｌ．: ＰＮＡＳ Ｖｏｌ．９１, 1994, ｐｐ．１１７４３-１１７４７ *
JPN6012016686; Ｈａｎ，　Ｋ-Ｊ．　ｅｔ　ａｌ．: Ａｒｃｈ．　Ｐｈａｒｍ．　Ｒｅｓ． Ｖｏｌ．２８，　Ｎｏ．２, 2005, ｐｐ．２０９-２１５ *
JPN6012016688; Ｇｌｅｎｎｏｎ，　Ｒ．Ａ．　ｅｔ　ａｌ．: Ｍｅｄ．　Ｃｈｅｍ．　Ｒｅｓ． Ｖｏｌ．１３, 2004, ｐｐ．７４-７７ *
JPN6012016690; Ｗａｎｇ，　Ｈ．　ｅｔ　ａｌ．: Ｎａｔｕｒｅ　Ｍｅｄｉｃｉｎｅ Ｖｏｌ．１０，　Ｎｏ．１１, 2004, ｐｐ．１２１６-１２２１ *

Also Published As

Publication number Publication date
NZ572366A (en) 2012-02-24
EP2801358A3 (en) 2015-03-04
US20090197921A1 (en) 2009-08-06
CN101437515B (zh) 2016-04-20
US20160008347A1 (en) 2016-01-14
BRPI0621650A2 (pt) 2011-12-20
CA2651580A1 (en) 2007-11-15
DK2801360T3 (en) 2018-07-23
EP2801360B1 (en) 2018-04-25
WO2007129879A1 (es) 2007-11-15
ES2683323T3 (es) 2018-09-26
US20120270907A1 (en) 2012-10-25
CN101437515A (zh) 2009-05-20
MX2008011473A (es) 2008-09-24
EP2801360A2 (en) 2014-11-12
EP2801359A3 (en) 2015-05-06
KR20130116374A (ko) 2013-10-23
EP2801359A2 (en) 2014-11-12
EP2801360A3 (en) 2015-03-04
CA2651580C (en) 2016-01-19
US20160279116A1 (en) 2016-09-29
AU2006343439B2 (en) 2013-05-16
EP2801358A2 (en) 2014-11-12
AU2006343439A1 (en) 2007-11-15
EP2027860A1 (en) 2009-02-25

Similar Documents

Publication Publication Date Title
ES2614287T3 (es) Lixisenatida como terapia adicional a la insulina basal en diabetes de tipo 2
US20160279116A1 (en) Therapeutic uses of nicotine
Huang et al. Remote ischemic postconditioning improves myocardial dysfunction via the risk and safe pathways in a rat model of severe hemorrhagic shock
Marks Nonthyroidal illness syndrome in children
EP1656120A1 (en) Compositions comprising components coated with a liquid impermeable but gas permeable layer, use thereof for treating cutaneous and other exocrine gland diseases
Tchirikov et al. Hyperbaric oxygenation and glucose/amino acids substitution in human severe placental insufficiency
CN113908161B (zh) 钩吻素子用于治疗脓毒症的用途
RU2442584C2 (ru) ИСПОЛЬЗОВАНИЕ НИКОТИНА, ЕГО АНАЛОГОВ, ПРЕДШЕСТВЕННИКОВ И ПРОИЗВОДНЫХ ПРИ ЛЕЧЕНИИ РАЗЛИЧНЫХ ПАТОЛОГИЧЕСКИХ ПРОЦЕССОВ, ПОДДАЮЩИХСЯ ЛЕЧЕНИЮ, ПУТЕМ ВВЕДЕНИЯ α-MSH ДЛЯ ПРОФИЛАКТИЧЕСКИХ ИЛИ ТЕРАПЕВТИЧЕСКИХ ЦЕЛЕЙ
CN104524544B (zh) 一种多肽在治疗糖尿病中的应用
WO2023087421A1 (zh) 一种聚合血红蛋白在制备治疗缺血性脑卒中药物的应用
KR20090006069A (ko) 예방적 또는 치료적 형태로 투여된 α-ＭＳＨ를 사용하여 개선시킬 수 있는 다양한 병리 과정을 치료하기 위한 니코틴, 그의 유사체, 그의 전구체 또는 그의 유도체의 용도
CN112076191A (zh) 凝血酶抑制剂在治疗缺血性脑卒中的新用途
CN107648236B (zh) 一种预防或治疗缺血/再灌注损伤的药物组合物及应用
JP6153838B2 (ja) 血管透過性抑制剤
AU2022207001B2 (en) Application of cilostazol-containing composition in preparing drug for treating cerebrovascular disease
KR102322102B1 (ko) 염증성 질환의 예방, 개선 또는 치료용 조성물
CN106860444A (zh) 3,4,7‑三羟基异黄酮或3‑甲氧基大豆素在制备抑制炎症和脑缺血药物的应用
RU2240808C1 (ru) Способ лечения диабетической нейропатии
CN118662495A (zh) Don在制备治疗脑缺血损伤药物中的应用
Zhu et al. Case Report Severe allergic reaction caused by succinylated gelatin during gastric cancer surgery and review of 31 cases
MACLEOD et al. THE AMERICAN JOUR~ NALOF PHYSIOLOGY
Goţia Anaphylaxis in child.
Correia 1 Organic Response to Stress
Teplan et al. PP093 BETTER RESULTS OF KETO AMINO ACIDS AND EXERCISE INTERVENTION ON MUSCLE/FAT TISSUE METABOLISM IN PERITONEAL DIALYSIS PATIENTS AFTER KIDNEY TRANSPLANTATION
Hayashi et al. Mistakes and Pitfalls of Brain Hypothermia Treatment

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110131

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120403

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120703

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120710

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120802

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20130205

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130611